Romidepsin

Mesothelioma

National Cancer Institute (NCI)Small moleculePhase 1Dormant

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

56 Active assets in the Mesothelioma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide National Cancer Institute (NCI)	Phase 2	BB
Fludarabine National Cancer Institute (NCI)	Phase 2	B
Nivolumab Orion Corporation, Orion Pharma	Phase 2	B
Pembrolizumab Genmab	Phase 2	B
FLUDEOXYGLUCOSE National Cancer Institute (NCI)	Phase 2	B

View all 50 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant

BBB

Indicative ·

76 / 100

Recurrent Mycosis Fungoides/Sezary SyndromeDormant

BBB

Indicative ·

75 / 100

Multiple Myeloma and Plasma Cell NeoplasmDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.